Tag Archives: biotech regulation

JOBS Act Deconstructed: Confidential Filing

AB23475

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. Any company conducting a public offering must file a registration statement, called an S-1, with the SEC.  The purpose of this document is to inform investors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

JOBS Act Deconstructed: Testing-the-Waters

87881842

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act enables companies to promote themselves to potential investors in advance of their IPO. Prior to the JOBS Act, companies conducting a public offering Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

JOBS Act Deconstructed: Regulatory Relief

Capitol

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act marks a key departure from the previous one-size-fits-all regulatory approach for companies conducting a public offering.  Emerging growth companies (EGCs) are now subject Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

“When Genetic Engineering Came Of Age”

insulin

October 29 was the 30th anniversary of the approval by the Food and Drug Administration (FDA) of human insulin synthesized in genetically engineered bacteria. In an article for Forbes, Henry Miller, the founding director of the FDA’s Office of Biotechnology, marked the anniversary and commented on today’s regulatory environment: “Regulators have adopted a highly risk-averse and even adversarial mindset, few new drugs are approved without convening extramural advisory committees, and decisions are sometimes hijacked by Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

How to Become a Global Biotech Leader: Innovation and the Worldview Report

fareed

What are the BRICS of the future? Latin America, Korea, North Africa, Thailand, Turkey? Scientific American’s 2012 Worldview contains a special section on Emerging Markets 2.0 and an exploration of countries that are showing promise for future development and an on-the-ground look at some of the science parks, incubators, research centers, or other hot spots of innovation that are coming into their own. With the release of Worldview Report and Scorecard at the 2012 BIO Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,